18 October 2020>: Clinical Research
Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
Yongxiang Zhang ABCDE , Yuechuan Li AEFG* , Zhen Ye BD , Hui Ma CFDOI: 10.12659/MSM.925278
Med Sci Monit 2020; 26:e925278
Table 2 The exacerbation rate in 1 year and GOLD groups in the patients with COPD.
Mild (n=8) | Moderate (n=24) | Severe (n=8) | |
---|---|---|---|
None | 7 (17.5) | 15 (37.5) | 3 (7.5) |
Once | 1 (2.5) | 6 (15) | 2 (5) |
Twice | 0 (0) | 3 (7.5) | 2 (5) |
Thrice | 0 (0) | 0 (0) | 1 (2.5) |
A | 7 (17.5) | 12 (30) | 0 |
B | 1 (2.5) | 9 (22.5) | 5 |
C | 0 (0) | 2 (5) | 1 (2.5) |
D | 0 (0) | 1 (2.5) | 2 (5) |
GOLD – Global Initiative for Obstructive Lung Disease. |